6月5日A股投資避雷針︱唯捷創芯:股東貴人資本及其一致行動人擬減持不超3%股份
金凱生科股東啟鷺投資擬減持不超3%股份;新華聯股東湖南華建擬減持983.97萬股;科興製藥股東科益醫藥擬減持不超3.00%股份;唯捷創芯股東貴人資本及其一致行動人擬減持不超3%股份;聯測科技實際控制人的一致行動人擬合計減持不超過1%股份;大參林股東柯金龍擬減持不超過2%股份;*ST新元子公司天津萬向部分資產被查封;泰爾股份控股股東、實控人解除留置並變更為責令候查

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.